Ahr activation through systemic administration of FICZ activated IL-22 producing CD8+ T cells (Tc22 cells), which have enhanced anti-tumor effects, though the cell extrinsic effect of FICZ on other cell populations remains possible (38). This evidence concerns the gene CD8A and neoplasm.